Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Lindemann

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
The Journal of Laboratory and Clinical Medicine|February 1, 1996
Renal expression of a transforming growth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouseV H Gattone, K A Kuenstler, G W Lindemann, et al.
Deutsche Medizinische Wochenschrift (1946)|June 26, 1992
[Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma]T M Löffler, F W Korsten, H E Reis, et al.
Onkologie|June 4, 2005
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III studyG Hartung, R-D Hofheinz, Y Dencausse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2008
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trialO Gluz, U A Nitz, N Harbeck, et al.
Nucleic Acids Research|January 16, 1999
Identification of differentially expressed mRNAs in human fetal liver across gestationK Malhotra, K R Luehrsen, L L Costello, et al.
European Journal of Haematology|April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsEMarc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Leukemia|July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsEHartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
The Journal of Laboratory and Clinical Medicine|February 1, 1996
Renal expression of a transforming growth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouseV H Gattone, K A Kuenstler, G W Lindemann, et al.
Deutsche Medizinische Wochenschrift (1946)|June 26, 1992
[Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma]T M Löffler, F W Korsten, H E Reis, et al.
Onkologie|June 4, 2005
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III studyG Hartung, R-D Hofheinz, Y Dencausse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2008
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trialO Gluz, U A Nitz, N Harbeck, et al.
Nucleic Acids Research|January 16, 1999
Identification of differentially expressed mRNAs in human fetal liver across gestationK Malhotra, K R Luehrsen, L L Costello, et al.
European Journal of Haematology|April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsEMarc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Leukemia|July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsEHartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
Pageof 8